CTRI/2024/02/063203Not yet recruitingUnknown
Safety and efficacy of sacubitril/valsartan for systemic right ventricular dysfunction – a prospective observational study - Nil
Pediatric Cardiac Society of India0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Unknown
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
Inclusion Criteria
- •After obtaining written informed consent, all consecutive patients with systemic right ventricular dysfunction,
- •ie, systemic right ventricular ejection fraction (sRV EF) =40% or fractional area change (FAC) =35%, assessed
- •by ECHO would be included.
Exclusion Criteria
- •1. Univentricular physiology
- •2. Systolic blood pressure < 90mmHg or <5th centile for age and height (whichever is lower)
- •3. GFR < 30ml/min/1.73m2
- •4. Serum potassium > 5.5 mEq/L
- •5. Previous intolerance to ACEi/ARB/ARNI
Investigators
Similar Trials
Not yet recruiting
Phase 1
Safety and efficacy of Sacubitril/Valsartan in blood pressure control of dialysis patientsCTRI/2020/02/023116Postgraduate Institute of Medical Education and Research
Recruiting
Phase 4
To assess the effectiveness and safety of adding sacubitril/valsartan to the standard treatment for the heart failure patientsCTRI/2023/07/055325Pt B.D. Sharma UHS Rohtak
Completed
Unknown
The efficacy of sacubitril/valsartan in patients with poorly controlled essential hypertension.HypertensionJPRN-UMIN000052604Tachibanadai clinic55
Recruiting
Phase 2
Investigating the effect of valsartan sacubitril on left ventricular functioIRCT20240117060713N1Ahvaz University of Medical Sciences92
Completed
Unknown
Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with HypertensioEnd-stage renal failureJPRN-UMIN000049348Kansai Medical University27